What question did this study set out to answer?

This research aims to assess real-world outcomes following BCMA-directed therapy failure in relapsed multiple myeloma patients.

June 17, 2026Current OncologyOpen Access

Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC

View Full Paper

Ask AI

Bookmark

This research aims to assess real-world outcomes following BCMA-directed therapy failure in relapsed multiple myeloma patients.
Conducted three retrospective multicenter studies focusing on different therapies in BDT-exposed patients.
Evaluated overall response rates and survival outcomes for CAR-T therapy vs. TCEs, and teclistamab vs. BDT-naïve patients.
Examined talquetamab outcomes based on treatment timings and patient history.
CAR-T therapy showed superior overall response rate (79% vs. 51%, p < 0.001) and median overall survival (30 vs. 12 months, p = 0.008) compared to TCEs.
Teclistamab had lower ORR in BDT-exposed patients (53% vs. 68%, p = 0.02) and shorter median PFS (2.5 vs. 9.7 months, p = 0.01) than BDT-naïve patients.
Talquetamab achieved an ORR of 68.3%, with lower response rates when administered within 6 months of BDT.

No takes yet. Share an insight, caveat, or question.

Retrospective analyses evaluate effectiveness of BCMA therapies and sequencing strategies for multiple myeloma.

Youssef et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark